{"ascites": 4.53, "blood creatinine increased": 2.41, "bone pain": 2.3, "breast cancer metastatic": 34.46, "cytomegalovirus infection": 17.56, "dehydration": 2.38, "disease progression": 5.17, "drug interaction": 4.15, "drug intolerance": 4.56, "drug level increased": 4.64, "drug resistance": 6.29, "general physical health deterioration": 3.21, "hypothyroidism": 2.59, "immunosuppressant drug level increased": 39.97, "interstitial lung disease": 3.18, "leukopenia": 3.35, "lung disorder": 2.4, "lung infiltration": 10.69, "maligt neoplasm progression": 26.02, "metastases to bone": 40.86, "metastases to liver": 62.88, "metastases to lung": 47.64, "metastases to lymph nodes": 31.22, "metastatic renal cell carcinoma": 20.86, "mouth ulceration": 5.29, "mucosal inflammation": 9.76, "neoplasm progression": 8.2, "neuroendocrine tumour": 69.09, "palmar-plantar erythrodysaesthesia syndrome": 5.77, "pancreatic neuroendocrine tumour": 151.94, "pik3ca-activated mutation": 341.85, "pleural effusion": 3.7, "pneumonitis": 16.76, "product use in unapproved indication": 3.85, "renal cell carcinoma": 22.56, "renal impairment": 2.44, "respiratory failure": 2.8, "stomatitis": 7.48, "thrombocytopenia": 2.24, "toxicity to various agents": 2.38, "treatment failure": 2.67}